Zydus Lifesciences (ZYDUSLIFE) Q4 01/02 earnings summary

Executive summary

• FY2001-02 standalone sales rose 15.7% to Rs 5,888 mn; PBIDT increased 18.8% to Rs 1,003 mn, while net profit reached Rs 672 mn.

• Consolidated sales rose 61.7% to Rs 8,732.6 mn and net profit increased 15.3% to Rs 668.6 mn, largely reflecting German Remedies joining the group.

Financial highlights

• Standalone PBT was Rs 733.7 mn versus Rs 708.1 mn; growth was restrained by lower interest income and prior-year investment-sale gains, while tax provision rose 17.8%.

• Exports including incentives rose 40% to Rs 958 mn; R&D spending increased 25% to Rs 415 mn, equal to 7% of sales.

• Proposed equity dividend was 70% per Rs 5 share; EPS was Rs 11.27 standalone and Rs 11.22 consolidated.

Outlook and guidance

• Strategic priorities: regulated-market exports, research-led growth, domestic high-growth therapies, and integration-driven cost and facility rationalisation.

• Moraiya’s U.K. MCA approval supports exports to the U.K. and Europe; Banyan’s USFDA-approved plant and U.S. marketing base support entry into U.S. generics.

• Improved German Remedies performance and cost, supply-chain, and asset initiatives were expected to benefit FY2002-03 results; VaxiRab was slated for launch in July 2002.